Top 3 Australian Growth Stocks With Earnings Growth Over 27%

Australian inflation has returned to 4%, and interest rates are at a 15 year high of 4.6%. As a result, reliable growth is suddenly harder to find. That is why investors are paying closer attention to fast growing businesses where insiders own a meaningful stake and share the same risks as outside shareholders. This article highlights three stocks from that group that may be worth a closer look now.

The three stocks below are just a starting sample, since the full screen surfaced 112 more businesses with similarly strong growth stories and meaningful insider ownership that are not covered here.

To go straight to the source and identify your own highest conviction ideas, analyze the Fast Growing Stocks With High Insider Ownership screener.

Liontown (ASX:LTR)

Liontown is focused on lithium, with the Kathleen Valley project giving the company direct exposure to demand for EV battery materials. It generates A$639 million from mineral exploration and development in Australia and carries a market value of about A$3.0b.

Liontown fits this screener because its Kathleen Valley lithium project is not just large, it is being fine tuned for better efficiency. This is where faster-growing stories can distinguish themselves from the pack.

"The company has initiated trials with higher contamination ore, achieving higher lithium recovery rates while maintaining strong recovery even with lower-grade material, which could improve net margins by optimizing processing costs over time."

What matters from here is how one pressure on future profitability and cash generation ultimately lands.

That inflection point is exactly what the full narrative for Liontown unpacks, revealing how processing gains, capital needs and pricing risks could reshape Liontown’s trajectory.

PDI Gold (ASX:PDI)

PDI Gold is a West African-focused gold producer built around the Kiniéro Gold project in Guinea, a growth engine that aligns closely with the screener’s fast growth and insider optimism theme. It carries a market value of about A$4.7b.

PDI Gold brings something different to this screen, because investors are not just looking at one mine. They are looking at a growing West African platform that insiders appear confident can scale from here.

"The merger with Robex creates a larger platform with two producing mines and the Bankan development project, which can support higher group gold output over time and provide a broader base for revenue and earnings."

What really matters for PDI Gold now is how one unresolved funding and dilution pressure ultimately shapes future cash generation and shareholder outcomes.

That funding question is exactly where the full narrative for PDI Gold shows how capital decisions could influence PDI Gold's path, either by expanding its opportunities or limiting its potential.

Telix Pharmaceuticals (ASX:TLX)

Telix Pharmaceuticals is building a precision radiopharmaceutical platform, with its fast-growing diagnostic and therapeutic pipeline aligning closely to the screener’s focus on growth supported by confident management and analyst views. The business generated about $705 million from Precision Medicine and $277 million from Manufacturing Solutions, and it is valued at roughly A$5.5b.

Telix Pharmaceuticals fits this screener because its radiopharmaceutical therapies and PET diagnostics are not a side project. They sit at the center of how the group is trying to grow faster than the broader market, backed by a management team that keeps committing capital to this same theme.

"Their primary revenue generating imaging agents: 'Illuccix' and 'Gozellix', are utilised in 23+ countries worldwide, including key markets such as the U.S, Europe, China and Japan, with revenue figures of $803.8m (USD) in the 2025 Financial Year (within their already upgraded guidance range) provided for FY25, a cash balance of $141.9m (USD), and the potential growth of Gozellix as its launch into the U.S expands."

What could really reshape Telix Pharmaceuticals from here is how one pressure on future pricing power and margins responds to the broader competitive push.

That pressure point is exactly where the full narrative for Telix Pharmaceuticals maps how Telix Pharmaceuticals’ pricing power, pipeline potential and competitive risks could be diverging from what today’s headlines suggest.

Seeking Alternatives Before The Crowd?

Fresh ideas move fast and slow research can mean watching the next breakout fly without you. Scan these curated shortlists while it matters and get in early.

• Target reliable income streams by reviewing a curated 3 dividend fortresses that focuses on durable payouts investors often chase only after the yields are already dropping.
• Ride structural demand in electrification by checking a hand picked 17 top copper producer stocks before copper related opportunities are fully caught by the broader market.
• Position for potential AI momentum by analysing carefully filtered 88 AI infrastructure stocks while the theme is still under the radar for now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com